|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
22
|
|
pubmed:dateCreated |
2009-11-13
|
|
pubmed:abstractText |
Lipocalin 2 (LCN2; also known as NGAL) is a secreted glycoprotein and its elevated expression has been observed in breast cancers. However, the importance of LCN2 in breast tumorigenesis is unclear. Here, we employed a spontaneous mammary tumor mouse model showing that MMTV-ErbB2(V664E) mice lacking mouse LCN2 had significantly delayed mammary tumor formation and metastasis with reduced matrix metalloproteinase-9 activity in the blood. LCN2 expression is upregulated by HER2/phosphoinositide 3-kinase/AKT/NF-kappaB pathway. Decreasing LCN2 expression significantly reduced the invasion and migration ability of HER2(+) breast cancer cells. Furthermore, injecting an anti-mouse LCN2 antibody into mice bearing established murine breast tumors resulted in significant blockage of lung metastasis. Our findings indicate that LCN2 is a critical factor in enhancing breast tumor formation and progression possibly in part by stabilizing matrix metalloproteinase-9. Our results suggest that inhibition of LCN2 function by an inhibitory monoclonal antibody has potential for breast cancer therapy, particularly by interfering with metastasis in aggressive types of breast cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1538-7445
|
|
pubmed:author |
pubmed-author:ArlinghausRalph BRB,
pubmed-author:FeigBarryB,
pubmed-author:HuLimeiL,
pubmed-author:JianhuaHuH,
pubmed-author:LengXiaohongX,
pubmed-author:LinHuiH,
pubmed-author:PusztaiLajosL,
pubmed-author:SymmansW FraserWF,
pubmed-author:TianDingD,
pubmed-author:UrenCC,
pubmed-author:WuYunY,
pubmed-author:ZhangWeiW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
8579-84
|
|
pubmed:meshHeading |
pubmed-meshheading:19887608-Acute-Phase Proteins,
pubmed-meshheading:19887608-Animals,
pubmed-meshheading:19887608-Blotting, Western,
pubmed-meshheading:19887608-Breast Neoplasms,
pubmed-meshheading:19887608-Cell Line, Tumor,
pubmed-meshheading:19887608-Female,
pubmed-meshheading:19887608-Flow Cytometry,
pubmed-meshheading:19887608-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:19887608-Humans,
pubmed-meshheading:19887608-Immunohistochemistry,
pubmed-meshheading:19887608-Lipocalins,
pubmed-meshheading:19887608-Matrix Metalloproteinase 9,
pubmed-meshheading:19887608-Mice,
pubmed-meshheading:19887608-Mice, Knockout,
pubmed-meshheading:19887608-NF-kappa B,
pubmed-meshheading:19887608-Neoplasm Invasiveness,
pubmed-meshheading:19887608-Oncogene Proteins,
pubmed-meshheading:19887608-Receptor, erbB-2,
pubmed-meshheading:19887608-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:19887608-Signal Transduction
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.
|
|
pubmed:affiliation |
Department of Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77054, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
